Research conducted at the Emory Transplant Center over the years has led to medical and surgical treatments that restore the lives of an ever increasing number of transplant patients at Emory and beyond. And fiscal year 2013 was no less spectacular.
The 50 Emory Transplant Center faculty researchers and their postdoctoral students and staff stretched each research dollar to the limit, and created a lot of bang for the buck. They published 82 papers in 52 journals in fiscal year 2013, and twenty-eight faculty were principal investigators on an active award. Leading research faculty members — Drs. Stuart Knechtle, Allan Kirk, Leslie Kean, Ken Newell, and Ken Brigham — had a total of $11.9 million in funding last year to develop many advances. We are truly shaping the field.
Even with the recent government shutdown, the future of transplant research here in FY2014 looks positive. “Despite the worst year in federal research funding since 1931, the Emory Transplant Center is currently enrolling in the largest number of clinical trials in our history — 29 studies,” Carlson says, “Also, the ETC is the leading site in the country enrolling patients in a hepatic support device trial, which is directed by Dr. Ram Subramanian.” Overall, ETC faculty are participating in 45 kidney, liver, islet, composite tissue, lung, and heart transplantation and infectious disease research studies. And Emory’s transplant biorepository core is involved in 39 multicenter studies.
“In the end, the single most important factor is that the ETC has been able to sustain a high impact research portfolio that spans basic, translational, and clinical science research,” Carlson says. “We continue to be exceptional stewards of the investments entrusted to us. Congratulations to everyone involved in research for making such a big impact in FY2013, and thank you for your continued dedication to advancing the field.”